Abstract: The resent disclosure provides an OLED substrate, a photo mask, and a method of manufacturing the OLED substrate. In one embodiment, an OLED substrate includes: a base substrate; an anode layer on the base substrate; a pixel defining layer on the anode layer, the pixel defining layer having a pattern opening area, the pattern opening area including a plurality of pixel openings arranged in an array manner; and a light-emitting layer formed on the pixel defining layer by evaporation; wherein the pattern opening area has an inward contraction structure with respect to a regular pixel opening area structure in which a plurality of pixel openings are arranged in a manner of an regular array where rows in the regular array are equally spaced from each other and are parallel to each other and columns in the regular array are equally spaced from each other and are parallel to each other.

Abstract: Systems, methods, and computer-readable media for providing cross-domain assurance for networks in different network domains. In some embodiments, a method can include collecting first fabric data for a first network in a first network domain and second fabric data for a second network in a second network domain. The second fabric data for the second network can be normalized based on the first network domain to create normalized second fabric data. The first fabric data can then be correlated with the normalized second fabric data to create correlated fabric data. Subsequently, assurance can be provided across the first network in the first network domain and the second network in the second network domain using the correlated fabric data.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: A displaying base plate includes a displaying region and a non-displaying region; the non-displaying region includes a substrate, and a first wiring unit, a first planarization part, at least one blocking wall, a second planarization part and a packaging layer located on the substrate; the first wiring unit is provided with a slot; the first planarization part and the blocking wall are provided on one side of the first wiring unit further away from the substrate; the first planarization part is closer to the displaying region than the blocking wall; orthographic projections of the first planarization part on the substrate and the blocking wall on the substrate do not intersect or overlap; the second planarization part is configured to at least fill and level up the slot in the first wiring unit that is located at the region between the first planarization part and the blocking wall.

Abstract: Systems, methods, and computer-readable media for providing cross-domain assurance for networks in different network domains. In some embodiments, a method can include collecting first fabric data for a first network in a first network domain and second fabric data for a second network in a second network domain. The second fabric data for the second network can be normalized based on the first network domain to create normalized second fabric data. The first fabric data can then be correlated with the normalized second fabric data to create correlated fabric data. Subsequently, assurance can be provided across the first network in the first network domain and the second network in the second network domain using the correlated fabric data.

Abstract: The present invention relates to a board assembly used for a base station antenna and a base station antenna including such a board assembly. The board assembly includes a first circuit board (3) and a second circuit board (4), and the first circuit board and the second circuit board are spaced apart from each other. The first circuit board has a plurality of first electrical connectors, the second circuit board has a plurality of second electrical connectors, and the first electrical connectors and the second electrical connectors are electrically connected by a plurality of coaxial cable assemblies (5). Each coaxial cable assembly extends between the first circuit board and the second circuit board, and includes a coaxial cable, a first corresponding electrical connector matching the first electrical connector on a first end of the coaxial cable, and a second corresponding electrical connector matching the second electrical connector on a second end opposite to the first end on the coaxial cable.

Abstract: Compounds which are thiazole and triazole derivatives are disclosed, including compounds of the following genus: The compounds are inhibitors of hematopoietic cell kinase (HCK) and exhibit anti-fibrotic and anti-proliferative effects. They are useful in the treatment of a variety of disorders, including a fibrosis or a fibrotic disease, such as renal fibrosis.

Abstract: A heat exchange flue, having a top flue gas chamber (1), a bottom flue gas chamber (10) and a heat exchange section (H) located therebetween. The heat exchange section (H) comprises a heat exchange tube bundle (4) located in the middle, and a left side flue (5) and a right side flue (12) which are located at two sides of the heat exchange tube bundle (4). The axis of the heat exchange tube bundle (4) is positioned in a vertical plane extending substantially forward and backward, allowing the flue gas to laterally flush against the surfaces of heat exchange tubes. The left and right side flues (5, 12) are in a vertical box shape, the flues are each provided with a plurality of flue gas dampers (3) which are vertically arranged at intervals in a substantially horizontal alignment. Each of the flue gas dampers (3) is provided with a flue gas damper frame (13) for defining a flue gas port (2) and a flue gas port opening/closing device capable of selectively opening and closing the flue gas port (2).

Abstract: A memory fault detection method includes: receiving a first interrupt signal sent when a count value of a first leaky bucket counter of a server reaches a first threshold; disabling an interrupt switch of the first leaky bucket counter; enabling the interrupt switch of the first leaky bucket counter after the interrupt switch of the first leaky bucket counter has been disabled for a preset time and the count value of the first leaky bucket counter is reset to zero; receiving a second interrupt signal sent when a count value of a second leaky bucket counter reaches a second threshold; if the second leaky bucket counter and the first leaky bucket counter are a same leaky bucket counter, and the second rank and a first rank are a same rank, determining that a hardware fault occurs in the first rank.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.

Abstract: Systems, methods, and computer-readable media for providing cross-domain assurance for networks in different network domains. In some embodiments, a method can include collecting first fabric data for a first network in a first network domain and second fabric data for a second network in a second network domain. The second fabric data for the second network can be normalized based on the first network domain to create normalized second fabric data. The first fabric data can then be correlated with the normalized second fabric data to create correlated fabric data. Subsequently, assurance can be provided across the first network in the first network domain and the second network in the second network domain using the correlated fabric data.